Oramed Pharmaceuticals Inc.

NasdaqCM ORMP

Oramed Pharmaceuticals Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 142.30 M

Oramed Pharmaceuticals Inc. Cash and Short-Term Investments is USD 142.30 M for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Oramed Pharmaceuticals Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 159.55 M, a 69.48% change year over year.
  • Oramed Pharmaceuticals Inc. Cash and Short-Term Investments for the quarter ending August 31, 2021 was USD 94.14 M, a 135.94% change year over year.
  • Oramed Pharmaceuticals Inc. Cash and Short-Term Investments for the quarter ending August 31, 2020 was USD 39.90 M.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
Loading...
SV Wall Street
NasdaqCM: ORMP

Oramed Pharmaceuticals Inc.

CEO Mr. Nadav Kidron Esq.
IPO Date May 1, 2007
Location United States
Headquarters 1185 Avenue of the Americas
Employees 13
Sector Healthcare
Industries
Description

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Similar companies

PALI

Palisade Bio, Inc.

USD 1.36

-4.90%

PLX

Protalix BioTherapeutics, Inc.

USD 2.43

2.10%

ZURA

Zura Bio Limited

USD 1.88

6.82%

INZY

Inozyme Pharma, Inc.

USD 1.44

-1.37%

CKPT

Checkpoint Therapeutics, Inc.

USD 2.84

0.00%

MREO

Mereo BioPharma Group plc

USD 3.01

2.73%

TERN

Terns Pharmaceuticals, Inc.

USD 4.46

-3.88%

ARDX

Ardelyx, Inc.

USD 5.36

0.00%

IMMX

Immix Biopharma, Inc.

USD 1.94

-1.52%

LPTX

Leap Therapeutics, Inc.

USD 0.56

7.86%

CRVS

Corvus Pharmaceuticals, Inc.

USD 5.36

1.32%

IBRX

ImmunityBio, Inc.

USD 3.45

-0.58%

ALDX

Aldeyra Therapeutics, Inc.

USD 5.24

-2.96%

StockViz Staff

February 4, 2025

Any question? Send us an email